Answers are grounded in this paper and cite their sources.
Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management.
No takes yet. Share an insight, caveat, or question.
Lafarge et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: